- Attralus, a South San Francisco, CA-based biopharmaceutical company focused on creating medicines for systemic amyloidosis, raised $25m in Series A financing
- Then the round was led by venBio Partners
- Attralus expects to file IND applications for the two therapeutics programs by early 2022
- Attralus is a biopharmaceutical company whose proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose
- Richard Gaster, M.D., Ph.D., Partner at venBio, and Corey Goodman, Ph.D., Managing Partner at venBio, will join Attralus’s Board of Directors
- Attralus also focused on targeting common pathology in all systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis
